🚨 PD-L1 ≥50% NSCLC: Is pembrolizumab alone enough? · CBA Frontier Insights

Back to meeting Original

Back to meeting

Dr Rishabh Jain· @DrRishabhOnco · X·2026-10-25 21:43· 3 days agoScore70

Body

🚨 PD-L1 ≥50% NSCLC: Is pembrolizumab alone enough?

🔥 PERSEE Phase III | #ESMO26

Pembrolizumab + chemotherapy vs pembrolizumab alone:

📊 PFS: 16.1 vs 6.9 months (HR 0.56; p<0.001)

📊 OS: 50.2 vs 29.9 months (HR 0.77; CI crosses 1)

🎯 PFS benefit persisted even with PD-L1 ≥90%.

💡 Verdict: Strong PFS benefit, but OS advantage remains unproven.

@myesmo @ESMO_open @ASCO @oncoalert

Full paper link in comment below ⬇️

118 views · 3 likes · 1 repost · 0 replies

引用@

🚨 PD-L1 ≥50% in NSCLC: Is pembrolizumab alone enough? 🔥 PERSEE Phase III | #ESMO26 Concomitant publication in Annals of Oncology. Pembrolizumab + chemotherapy vs pembrolizumab alone: 📊 PFS: 16.1 vs 6.9 months (HR 0.56) 🎯 ORR: 77.5% vs 50.3% ⚠️ Grade ≥3 toxicity: 54% vs 19% OS: 50.2 vs 29.9 months (HR 0.77), not statistically significant. 💡 Verdict: Better disease control, but at a substantial toxicity cost. Is PD-L1 ≥50% alone sufficient to omit chemotherapy? @ESMO_open @myesmo @ASCO @oncoalert #ESMO26 #LungCancer

在 X 查看被引用的帖子

Source: Dr Rishabh Jain · x.com